Drug Profile
VN/14-1RA
Latest Information Update: 26 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Retinoic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Skin disorders
Most Recent Events
- 16 Sep 1999 New profile
- 16 Sep 1999 Preclinical development for Cancer in USA (Unknown route)
- 16 Sep 1999 Preclinical development for Skin disorders in USA (Unknown route)